Oculis Reports $268.7M Cash Runway and Privosegtor Breakthrough Therapy Designation
Oculis ended 2025 with $268.7 million in cash and short-term investments, backed by $210 million raised in 2025, providing runway into 2029 for its late-stage programs. The company gained FDA Breakthrough Therapy designation for Privosegtor and anticipates DIAMOND Phase 3 topline results in Q2 2026.
1. Financial Results and Cash Position
Oculis closed 2025 with CHF 213.0 million ($268.7 million) in cash, cash equivalents and short-term investments after raising $210 million through equity financings in February and November 2025. This strong balance sheet provides sufficient funding into 2029 to advance its late-stage ophthalmology and neuro-ophthalmology pipeline.
2. Privosegtor Breakthrough Therapy and PIONEER Program
Privosegtor received FDA Breakthrough Therapy designation for optic neuritis following Phase 2 ACUITY results, which showed significant vision improvements and neuroprotective benefits versus placebo. Oculis has launched the PIONEER registrational program, including three pivotal trials in optic neuritis and non-arteritic anterior ischemic optic neuropathy, targeting a U.S. market opportunity exceeding $7 billion.
3. OCS-01 DIAMOND Phase 3 Trials in DME
OCS-01 eye drops for diabetic macular edema have enrolled over 800 patients across two Phase 3 DIAMOND trials nearing completion. Topline results are expected in Q2 2026, aiming to address the 1.3 million underserved DME patients in a U.S. market valued at approximately $3 billion.
4. Licaminlimab Precision Medicine in Dry Eye Disease
The PREDICT-1 registrational trial for Licaminlimab has been initiated to evaluate a genotype-based approach in moderate to severe dry eye disease. Prior Phase 2 data showed up to five-fold greater sign improvement in TNFR1 genotype carriers, with topline results anticipated in Q4 2026.